Literature DB >> 34720152

Impact of Pharmacist-Directed Simplified Procalcitonin Algorithm on Antibiotic Therapy in Critically Ill Patients With Sepsis.

Julie Willmon1, Bibidh Subedi2, Ramy Girgis2, Myint Noe2.   

Abstract

PURPOSE: The purpose was to determine whether a simplified procalcitonin (PCT) algorithm guided by pharmacist recommendations reduces antibiotic duration of therapy in critically ill patients with suspected sepsis.
METHODS: This was a single-centered pre-post study conducted at a 1368-bed community teaching hospital in the United States. A prospective cohort with pharmacist intervention utilizing a simplified PCT algorithm was compared with a retrospective historical cohort with standard therapy. Adult patients admitted to the intensive care unit (ICU) with suspected sepsis who received intravenous antibiotics were included. A pharmacist recommended continuation or discontinuation of antibiotics based on the PCT level per our algorithm and full clinical assessment of the patient. Primary outcome was total duration of antibiotic therapy. Secondary outcomes were ICU and hospital length of stay (LOS), reinitiation of antibiotic therapy within 72 hours of discontinuation, and 28-day in-hospital mortality.
RESULTS: From September 2017 to May 2018, 360 patients were screened for eligibility. Of these, 26 patients were included in the PCT group and 26 patients in the standard therapy group. Baseline characteristics were similar between groups. A significant difference in duration of antibiotic therapy was detected with a median of 9 days in the PCT group versus 12 days in the standard therapy group (P = .02). There were no significant differences in secondary endpoints of ICU and hospital LOS, reinitiation of antibiotics at 72 hours, or 28-day mortality.
CONCLUSION: Use of a simplified PCT algorithm with pharmacist-guided recommendations significantly reduced the duration of antibiotic therapy in critically ill patients with sepsis.
© The Author(s) 2020.

Entities:  

Keywords:  critically ill; pharmacist; procalcitonin; sepsis, antibiotics

Year:  2020        PMID: 34720152      PMCID: PMC8554589          DOI: 10.1177/0018578720925385

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  16 in total

1.  Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial.

Authors:  Yahya Shehabi; Martin Sterba; Peter Maxwell Garrett; Kanaka Sundaram Rachakonda; Dianne Stephens; Peter Harrigan; Alison Walker; Michael J Bailey; Bronwyn Johnson; David Millis; Geoff Ding; Sandra Peake; Helen Wong; Jane Thomas; Kate Smith; Loretta Forbes; Miranda Hardie; Sharon Micallef; John F Fraser
Journal:  Am J Respir Crit Care Med       Date:  2014-11-15       Impact factor: 21.405

2.  Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.

Authors:  R Phillip Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven A Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Crit Care Med       Date:  2013-02       Impact factor: 7.598

3.  Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial.

Authors:  Lila Bouadma; Charles-Edouard Luyt; Florence Tubach; Christophe Cracco; Antonio Alvarez; Carole Schwebel; Frédérique Schortgen; Sigismond Lasocki; Benoît Veber; Monique Dehoux; Maguy Bernard; Blandine Pasquet; Bernard Régnier; Christian Brun-Buisson; Jean Chastre; Michel Wolff
Journal:  Lancet       Date:  2010-01-25       Impact factor: 79.321

4.  Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.

Authors:  Vandack Nobre; Stephan Harbarth; Jean-Daniel Graf; Peter Rohner; Jérôme Pugin
Journal:  Am J Respir Crit Care Med       Date:  2007-12-20       Impact factor: 21.405

5.  Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.

Authors:  Evelien de Jong; Jos A van Oers; Albertus Beishuizen; Piet Vos; Wytze J Vermeijden; Lenneke E Haas; Bert G Loef; Tom Dormans; Gertrude C van Melsen; Yvette C Kluiters; Hans Kemperman; Maarten J van den Elsen; Jeroen A Schouten; Jörn O Streefkerk; Hans G Krabbe; Hans Kieft; Georg H Kluge; Veerle C van Dam; Joost van Pelt; Laura Bormans; Martine Bokelman Otten; Auke C Reidinga; Henrik Endeman; Jos W Twisk; Ewoudt M W van de Garde; Anne Marie G A de Smet; Jozef Kesecioglu; Armand R Girbes; Maarten W Nijsten; Dylan W de Lange
Journal:  Lancet Infect Dis       Date:  2016-03-02       Impact factor: 25.071

6.  Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study.

Authors:  S Schroeder; M Hochreiter; T Koehler; A-M Schweiger; B Bein; F S Keck; T von Spiegel
Journal:  Langenbecks Arch Surg       Date:  2008-11-26       Impact factor: 3.445

7.  Practice Patterns and Outcomes Associated With Procalcitonin Use in Critically Ill Patients With Sepsis.

Authors:  David C Chu; Anuj B Mehta; Allan J Walkey
Journal:  Clin Infect Dis       Date:  2017-06-01       Impact factor: 9.079

Review 8.  Update on procalcitonin measurements.

Authors:  Michael Meisner
Journal:  Ann Lab Med       Date:  2014-06-19       Impact factor: 3.464

9.  Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study.

Authors:  Philipp Schuetz; Robert Birkhahn; Robert Sherwin; Alan E Jones; Adam Singer; Jeffrey A Kline; Michael S Runyon; Wesley H Self; D Mark Courtney; Richard M Nowak; David F Gaieski; Stefan Ebmeyer; Sascha Johannes; Jan C Wiemer; Andrej Schwabe; Nathan I Shapiro
Journal:  Crit Care Med       Date:  2017-05       Impact factor: 7.598

Review 10.  Procalcitonin as a biomarker of infectious diseases.

Authors:  Hyuck Lee
Journal:  Korean J Intern Med       Date:  2013-05-01       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.